The immune checkpoint blockade therapy (targeting PD1 or CTLA4) has been successfully applied in treating melanoma, lung cancer and kidney cancer, which acts on the dysfunction or exhaustion state of T cells [2, 3]. The gene discussed is PDCD1; the disease is melanoma.